Company News: Dendreon

Share this article:
Dendreon's Provenge prostate cancer vaccine, the first in a new class of cancer treatments that use the patient's own immune system, received FDA approval. The vaccine, approved for men with the advanced form of the disease, is designed to induce an immune response against prostatic acid phosphatase, an antigen expressed in most prostate cancers. Provenge (sipuleucel-T) belongs to a new therapeutic class called autologous cellular immunotherapies and could usher in an entirely new treatment paradigm for patients with cancer. Several other companies are developing immunotherapies targeting tumor antigens.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.